Elderly patients with schizophrenia and dementia patients with agitation ar
e frequently candidates for antipsychotic treatment. Conventional neurolept
ics have relatively little effect on negative symptoms and may cause consid
erable side effects, especially in elderly patients. The authors have found
a 29% cumulative annual incidence of tardive dyskinesia (TD) in middle-age
d and elderly outpatients treated with relatively low doses of conventional
neuroleptics. Newer antipsychotics are less likely to cause extrapyramidal
symptoms and may be associated with a lower risk of TD. They are generally
effective for both positive and negative symptoms and may also improve som
e aspects of cognition, but these drugs have their own side effects. Dosing
requirements for elderly patients tend to be much lower than those for you
nger adults.